4//SEC Filing
Danahy Kevin Patrick 4
Accession 0001437749-23-030250
CIK 0001625101other
Filed
Nov 2, 8:00 PM ET
Accepted
Nov 3, 5:41 PM ET
Size
9.6 KB
Accession
0001437749-23-030250
Insider Transaction Report
Form 4
Danahy Kevin Patrick
Chief Commercial Officer
Transactions
- Other
Stock Option (right to buy)
2023-11-01−130,000→ 0 totalExercise: $3.96Exp: 2033-10-23→ Common Stock (130,000 underlying) - Award
Stock Option (right to buy)
2023-10-23+130,000→ 130,000 totalExercise: $3.96Exp: 2033-10-23→ Common Stock (130,000 underlying) - Award
Stock Option (right to buy)
2023-11-01+460,000→ 460,000 totalExercise: $4.38Exp: 2033-11-01→ Common Stock (460,000 underlying)
Footnotes (3)
- [F1]The shares will vest in four equal annual installments on each of the first four annual anniversaries of the grant date, subject to the Reporting Person's continued service through each vesting date.
- [F2]Reporting Person was erroneously granted an option to acquire 130,000 shares on October 23, 2023, which option was cancelled by mutual agreement on November 1, 2023.
- [F3]100% vesting upon the earlier of (i) the six (6) year anniversary of the grant date, and (ii) the 1-year anniversary of a Company change of control.
Documents
Issuer
Pulse Biosciences, Inc.
CIK 0001625101
Entity typeother
Related Parties
1- filerCIK 0001913245
Filing Metadata
- Form type
- 4
- Filed
- Nov 2, 8:00 PM ET
- Accepted
- Nov 3, 5:41 PM ET
- Size
- 9.6 KB